https://www.biospace.com/article/wugen-ramps-up-off-the-shelf-gene-therapies-to-fight-cancer/#new_tab2021-01-26T23:46:40+00:00https://alloteratx.com/wugen-appoints-new-vice-president-and-head-of-nk-research-as-the-company-continues-to-expand-its-pipeline/2020-11-19T23:57:47+00:00https://alloteratx.com/wugen-adds-to-leadership-team-as-company-continues-to-lay-groundwork-for-future-expansion/2019-04-30T23:59:57+00:00https://alloteratx.com/wugen-expands-leadership-team-with-appointment-of-a-vice-president-of-research-and-development-and-a-vice-president-of-product-development/2019-03-26T00:01:58+00:00https://alloteratx.com/wugen-presents-new-data-for-key-car-t-platform-at-the-2019-transplantation-cellular-therapy-meetings-of-asbmt-and-cibmtr/2019-02-20T00:03:21+00:00https://alloteratx.com/wugen-presents-updated-preclinical-data-on-novel-allogeneic-car-t-platform-at-ash-annual-meeting/2018-12-03T00:06:14+00:00https://alloteratx.com/wugen-announces-exclusive-license-agreement-for-car-t-therapy-technologies-from-washington-university-in-st-louis/2018-11-13T00:08:16+00:00https://alloteratx.com/wugen-announces-presentations-at-american-society-of-hematology-annual-meeting/2018-11-01T00:10:13+00:00https://doi.org/10.1158/2159-8290.cd-20-0312#new_tab2020-12-06T19:54:43+00:00https://doi.org/10.1053/j.seminhematol.2020.11.003#new_tab2020-11-01T19:56:32+00:00https://doi.org/10.1182/blood.2020006619#new_tab2020-11-01T19:57:14+00:00https://doi.org/10.1016/j.beha.2019.101097#new_tab2019-12-01T20:10:37+00:00https://doi.org/10.1038/s41375-018-0065-5#new_tab2018-02-01T20:14:45+00:00https://doi.org/10.1016/j.bbmt.2016.11.018#new_tab2017-03-02T20:19:47+00:00https://doi.org/10.1126/scitranslmed.aaf2341#new_tab2016-02-01T20:21:36+00:00https://doi.org/10.1016/j.bbmt.2014.01.006#new_tab2014-04-01T20:31:46+00:00https://doi.org/10.1182/blood-2012-04-419283#new_tab2012-12-10T20:32:14+00:00https://alloteratx.com/wugen-appoints-jan-davidson-m-d-ph-d-as-chief-medical-officer-to-guide-the-companys-global-nk-and-t-cell-clinical-programs/2021-02-22T14:02:40+00:00https://alloteratx.com/wugen-announces-exclusive-license-agreement-for-their-memory-natural-killer-nk-cell-based-therapy-program-with-washington-university-in-st-louis/2021-02-22T14:03:18+00:00https://alloteratx.com/wugen-announces-the-appointment-of-companys-co-founder-matt-cooper-ph-d-as-chief-scientific-officer/2021-03-01T14:00:08+00:00https://alloteratx.com/wugen-announces-exclusive-license-agreement-with-hcw-biologics-for-cell-therapies-to-treat-cancer/2021-03-02T13:56:22+00:00https://www.technologynetworks.com/biopharma/articles/the-promise-of-natural-killer-cells-346227#new_tab2021-03-04T19:34:09+00:00https://www.bizjournals.com/stlouis/news/2021/03/02/st-louis-biotech-startup-wugen-inks-manufacturing.html#new_tab2021-03-02T19:37:18+00:00https://www.bizjournals.com/stlouis/news/2021/02/23/wugen-inks-deal-hires-csuite-executive.html#new_tab2021-02-25T19:40:42+00:00https://alloteratx.com/wugen-announces-exclusive-partnership-agreement-with-alpha-biopharma-in-asia-for-cell-therapies-to-treat-cancer/2021-03-08T13:59:02+00:00https://www.bioworld.com/articles/504652-alpha-biopharma-lands-deal-for-wugens-memory-nk-and-car-t-cells-for-asia?v=preview#new_tab2021-03-13T19:00:02+00:00https://www.technologynetworks.com/cancer-research/blog/the-development-of-natural-killer-cells-for-solid-tumor-treatment-347058#new_tab2021-03-26T17:37:52+00:00https://alloteratx.com/wugen-appoints-daniel-kemp-ph-d-as-chief-executive-officer/2021-04-14T13:18:44+00:00https://alloteratx.com/wugen-deploying-memory-nk-cells-against-cancer/2021-05-17T19:48:37+00:00https://pubmed.ncbi.nlm.nih.gov/34187852/#new_tab2021-06-30T20:31:31+00:00https://siteman.wustl.edu/cell-based-immunotherapy-shows-promise-against-melanoma/#new_tab2021-07-01T20:07:55+00:00https://alloteratx.com/wugen-raises-172-million-to-advance-clinical-stage-memory-nk-cell-platform-progress-best-in-class-aml-program-and-initiate-multiple-solid-tumor-trials/2021-07-15T07:00:53+00:00https://alloteratx.com/wugen-announces-data-presentation-at-the-63rd-annual-society-of-hematology-ash-annual-meeting/2021-11-05T00:25:05+00:00https://alloteratx.com/wugen-announces-data-presentation-at-the-society-for-immunotherapy-of-cancers-sitc-36th-annual-meeting/2021-11-09T12:56:23+00:00https://alloteratx.com/wugen-to-present-virtually-at-the-upcoming-jefferies-london-healthcare-conference/2021-11-10T13:00:34+00:00https://alloteratx.com/wugen-presents-new-preclinical-data-from-novel-memory-natural-killer-nk-platform-at-the-society-for-immunotherapy-of-cancers-sitc-36th-annual-meeting/2021-11-12T12:11:51+00:00https://alloteratx.com/wugen-presents-new-preclinical-data-supporting-the-safety-and-efficacy-of-wu-cart-007-for-t-cell-malignancies-at-the-63rd-annual-society-of-hematology-ash-annual-meeting/2021-12-13T22:02:49+00:00https://www.science.org/doi/10.1126/scitranslmed.abm1375#new_tab2022-02-25T19:38:38+00:00https://alloteratx.com/healthcare-conference/2022-03-09T12:57:25+00:00https://alloteratx.com/wugen-announces-first-patient-dosed-in-phase-1-2-trial-of-wu-cart-007-for-the-treatment-of-patients-with-r-r-t-all-lbl/2022-03-15T11:58:45+00:00https://alloteratx.com/wugen-to-present-at-the-innate-killer-summit-2022/2022-03-24T11:58:03+00:00https://alloteratx.com/wugen-to-participate-in-upcoming-april-investor-conferences/2022-04-07T11:56:41+00:00https://alloteratx.com/wugen-to-present-preclinical-data-on-wu-nk-101-at-the-european-hematology-association-eha-2022-hybrid-congress/2022-05-12T16:43:47+00:00https://alloteratx.com/wugen-to-participate-in-upcoming-june-investor-conferences/2022-06-01T11:54:23+00:00https://alloteratx.com/wugen-presents-new-preclinical-data-demonstrating-enhanced-anti-tumor-activity-of-wu-nk-101-at-the-european-hematology-association-eha-2022-hybrid-congress/2022-06-10T16:39:40+00:00https://alloteratx.com/wugen-receives-u-s-fda-fast-track-and-rare-pediatric-disease-designations-for-wu-cart-007-for-the-treatment-of-r-r-t-all-lbl/2022-07-19T11:56:50+00:00https://alloteratx.com/wugen-appoints-natalie-mount-ph-d-as-chair-of-the-board-of-directors/2022-08-25T12:15:54+00:00https://alloteratx.com/wugen-presents-preclinical-data-on-wu-nk-101-in-solid-tumor-models-at-the-european-society-for-medical-oncology-esmo-congress-2022/2022-09-10T12:00:38+00:00https://alloteratx.com/wugen-to-present-at-the-upcoming-jefferies-cell-genetic-medicine-summit/2022-09-23T12:00:36+00:00https://alloteratx.com/wugen-to-present-data-on-wu-nk-101-for-relapsed-refractory-acute-myelogenous-leukemia-at-the-american-society-of-hematologys-ash-64th-annual-meeting/2022-11-03T18:48:04+00:00https://alloteratx.com/wugen-to-present-data-characterizing-wu-nk-101-at-the-society-for-immunotherapy-of-cancers-sitc-37th-annual-meeting/2022-11-07T13:03:03+00:00https://alloteratx.com/wugen-to-present-at-the-upcoming-jefferies-london-healthcare-conference/2022-11-10T14:45:43+00:00https://alloteratx.com/wugen-presents-data-supporting-clinical-development-of-wu-nk-101-for-relapsed-refractory-aml-at-the-american-society-of-hematologys-ash-64th-annual-meeting/2022-12-11T14:42:27+00:00https://alloteratx.com/wugen-presents-data-on-wu-nk-101-in-combination-with-cetuximab-in-preclinical-models-of-advanced-colorectal-cancer-crc-at-asco-gastrointestinal-cancers-symposium/2023-01-21T21:39:50+00:00https://alloteratx.com/wugen-announces-ceo-transition/2023-03-21T11:49:29+00:00https://alloteratx.com/wugen-to-present-data-on-wu-nk-101-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023/2023-03-29T14:33:27+00:00https://alloteratx.com/wugen-presents-new-preclinical-data-reinforcing-anti-tumor-functionality-of-wu-nk-101-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023/2023-04-19T12:25:14+00:00https://alloteratx.com/wugen-appoints-industry-leader-mark-alles-as-chair-of-the-board-of-directors/2023-05-10T11:56:09+00:00https://alloteratx.com/wugen-announces-multiple-presentations-at-the-european-hematology-association-eha-2023-congress/2023-05-11T14:18:47+00:00https://alloteratx.com/wugen-presents-initial-data-from-first-in-human-phase-1-2-trial-of-wu-cart-007-at-the-european-hematology-association-eha-2023-congress/2023-06-09T11:15:35+00:00https://alloteratx.com/wugen-begins-first-in-human-phase-1-clinical-trial-of-wu-nk-101-its-lead-allogeneic-memory-natural-killer-nk-cell-therapy-for-patients-with-relapsed-or-refractory-r-r-acute-myeloid-leukemia-aml-2/2023-08-15T18:44:19+00:00https://alloteratx.com/wugen-to-present-new-clinical-data-for-wu-cart-007-and-preclinical-data-for-wu-nk-101-two-investigational-allogeneic-cell-therapies-for-challenging-hematologic-cancers-at-american-society-of-hematol/2023-11-02T14:53:09+00:00https://alloteratx.com/wugen-presents-latest-data-from-first-in-human-phase-1-2-trial-of-wu-cart-007-in-patients-with-difficult-to-treat-blood-cancers-at-american-society-of-hematology-annual-meeting/2023-12-11T18:39:36+00:00http://wugen.com/wp-content/uploads/2023/12/2023-ASH-WUCART7_FINAL.pdf#new_tab2023-12-13T00:22:57+00:00https://alloteratx.com/wugen-strengthens-executive-leadership-team-with-appointment-of-keith-vendola-m-d-m-b-a-as-chief-financial-officer/2024-01-03T13:10:45+00:00https://alloteratx.com/maxcyte-and-wugen-sign-strategic-platform-license-to-expedite-scale-up-of-clinical-and-commercial-manufacturing-of-wugens-investigational-allogeneic-off-the-shelf-cell-therapies-for-cancers/2024-01-30T00:10:21+00:00https://alloteratx.com/cellipont-bioservices-and-wugen-sign-agreement-for-the-clinical-manufacture-of-wugens-off-the-shelf-car-t-cellular-therapies/2024-03-14T14:14:50+00:00https://alloteratx.com/wugen-announces-rmat-and-prime-designations-for-wu-cart-007-to-accelerate-regulatory-reviews-and-plans-to-present-positive-phase-2-study-findings-at-european-hematology-association-eha-2024-in-june/2024-05-20T11:34:54+00:00https://alloteratx.com/phase-2-findings-show-wugens-investigational-allogeneic-car-t-wu-cart-007-was-highly-effective-and-surpassed-standard-of-care-in-treating-hard-to-treat-t-all-lbl-data-presented-today-at-eu/2024-06-14T11:39:49+00:00https://alloteratx.com/cherry-t-thomas-m-d-joins-wugen-as-chief-medical-officer-bringing-cell-therapy-expertise-across-clinical-development-regulatory-and-medical-affairs-as-the-company-embarks-on-a-pivotal-trial-for-its-in/2024-11-12T12:03:02+00:00https://alloteratx.com/wugen-to-initiate-a-pivotal-trial-for-its-investigational-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007-in-patients-with-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukem/2024-11-12T12:04:36+00:00https://alloteratx.com/wugen-to-present-clinical-data-at-the-2024-ash-annual-meeting-ahead-of-pivotal-trial-launch-of-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007/2024-12-05T12:00:31+00:00https://alloteratx.com/wugen-announces-appointment-of-jim-faulkner-ph-d-as-chief-technology-officer/2025-02-26T12:00:24+00:00https://alloteratx.com/wugen-announces-dosing-of-first-patients-in-pivotal-trial-of-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-wu-cart-007/2025-03-20T00:56:03+00:00https://alloteratx.com/wugen-secures-115-million-to-advance-pivotal-study-of-first-in-class-allogeneic-car-t-therapy-wu-cart-007/2025-08-27T10:53:02+00:00https://alloteratx.com/head-of-data-science-biometrics/2026-07-06T17:13:22+00:00https://alloteratx.com/wugen-to-present-correlative-data-and-long-term-follow-up-updates-for-off-the-shelf-allogeneic-cd7-targeted-car-t-cell-therapy-at-the-2025-ash-annual-meeting/2025-12-05T11:58:12+00:00https://alloteratx.com/u-s-fda-grants-to-wugens-wu-cart-007-breakthrough-therapy-designation-for-treatment-of-relapsed-or-refractory-t-cell-acute-lymphoblastic-leukemia-t-cell-lymphoblastic-lymphoma/2026-01-21T13:00:50+00:00https://alloteratx.com/wugen-selected-for-u-s-fda-chemistry-manufacturing-and-controls-development-and-readiness-pilot-program-to-support-manufacturing-readiness-of-soficabtagene-geleucel/2026-04-02T11:55:05+00:00https://alloteratx.com/senior-engineer-scientist-cmc-process-validation/2026-06-03T18:57:10+00:00https://pubmed.ncbi.nlm.nih.gov/40445850/#new_tab2026-07-03T19:51:50+00:00https://alloteratx.com/allotera-therapeutics-formerly-wugen-closes-35-million-financing-to-advance-off-the-shelf-car-t-therapies-for-t-cell-cancers/2026-07-07T21:33:54+00:00